Publications by authors named "Jan Walewski"

Claim this Profile
P
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.
Elżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, Jan Walewski

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
Emanuele Zucca, Luca Ceriani, Giovannino Ciccone, Alice Di Rocco, Maria Cristina Pirosa, Jan Walewski

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.
Benoit Tessoulin, James Harnett, Seok-Goo Cho, Michał Taszner, Tae Min Kim, Jan Walewski

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
Mats Jerkeman, Igor Aurer, Elias Campo, Chan Y Cheah, Jonathan Clark, Jan Walewski

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Value of Baseline Left Ventricular Global Longitudinal Strain for Cardiac Dysfunction in Patients with Moderate to High Risk of Cancer Therapy-Related Cardiovascular Toxicity.
Anna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, Agnieszka Maria Zebrowska, Slawomir Jasek, Jan Walewski

Pharmaceuticals (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Linmiao Jiang, Marco Ladetto, Olivier Hermine, Johanna C Kluin-Nelemans, Jan Walewski

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.
Anna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, Agnieszka Maria Zebrowska, Sławomir Jasek, Jan Walewski

Pharmaceuticals (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Won Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Jan Walewski

Nat Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.
Michael Northend, William Wilson, Kushani Ediriwickrema, Laura Clifton-Hadley, Wendi Qian, Jan Walewski

Lancet Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha.
Anna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, Agnieszka Maria Zebrowska, Sławomir Jasek, Jan Walewski

Int J Mol Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, Pip Patrick, June Warden, Jan Walewski

Br J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Won Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Jan Walewski

Nat Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet.
Vincent Ribrag, Dominique Bron, Grzegorz Rymkiewicz, Dieter Hoelzer, Judit Jørgensen, Jan Walewski

Lancet Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
Linmiao Jiang, Martin Dreyling, Olivier Hermine, Ulrich Mansmann, Jan Walewski

Br J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
Maurizio Martelli, Luca Ceriani, Giovannino Ciccone, Umberto Ricardi, Iryna Kriachok, Jan Walewski

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity.
Anna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, Agnieszka Maria Zebrowska, Agnieszka Jagiello-Gruszfeld, Jan Walewski

Cardiooncology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Jan Walewski

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal and Formic Acid as Commonly Altered in Cancer Patients.
Maria Kulecka, Paweł Czarnowski, Aneta Bałabas, Maryla Turkot, Kamila Kruczkowska-Tarantowicz, Jan Walewski

Int J Mol Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Martin Dreyling, Jeanette Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski

Lancet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Tadeusz Kubicki, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Jan Walewski

Pol Arch Intern Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study.
Anna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, Agnieszka Jagiello-Gruszfeld, Slawomir Jasek, Jan Walewski

PLoS One· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski

EClinicalMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski

Blood· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New molecular targets in Hodgkin and Reed-Sternberg cells.
Hummaira Sadaf, Maciej Ambroziak, Robert Binkowski, Jakkapong Kluebsoongnoen, Ewa Paszkiewicz-Kozik, Jan Walewski

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Beata Ostrowska, Katarzyna Domanska-Czyz, Joanna Romejko-Jarosinska, Michal Osowiecki, Lukasz Targonski, Jan Walewski

Br J Haematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis